A randomized phase ...
Clear all

A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer

2 Posts
2 Users
Joined: 9 years ago
Posts: 1190
Topic starter  

@Jun @dng050

Our previous study indicated that intravenous vitamin C (IVC) treatment concurrent with modulated electrohyperthermia (mEHT) was safe and improved the quality of life (QoL) of non-small-cell lung cancer (NSCLC) patients. The aim of this trial was to further verify the efficacy of the above combination therapy in previously treated patients with refractory advanced (stage IIIb or IV) NSCLC. A total of 97 patients were randomized to receive IVC and mEHT plus best supportive care (BSC) (n = 49 in the active arm, receiving 1 g/kg * d IVC concurrently with mEHT, three times a week for 25 treatments in total) or BSC alone (n = 48 in the control arm). After a median follow-up of 24 months, progression-free survival (PFS) and overall survival (OS) were significantly prolonged by combination therapy compared to BSC alone (PFS: 3 months vs 1.85 months, P < 0.05; OS: 9.4 months vs 5.6 months, P < 0.05). QoL was significantly increased in the active arm despite the advanced stage of disease. The 3-month disease control rate after treatment was 42.9% in the active arm and 16.7% in the control arm (P < 0.05). Overall, IVC and mEHT may have the ability to improve the prognosis of patients with advanced NSCLC.


Joined: 4 years ago
Posts: 1

Hi Daniel


Thank you very much for sharing this latest research. What struck me was the big difference between active and control arms in the OS graph, with 30% of the active cohort still alive after 35+ months. It's interesting that the treatment was only given for 9 weeks total (3 times per week, 25 treatments total), yet the effects were significantly long lasting...unless I'm reading the article wrong?


We will be starting Vitamin C infusions this weekend and hope to continue this weekly. Not fancying our chances of obtaining concurrent mEHT treatment, but nonetheless it is good to keep in the back of the mind.